Because JAK2 inhibition also has toxic effects (e.g., anemia, thrombocytopenia) that prevent many patients from obtaining the quality-of-life benefits from agents such as ruxolitinib, critical to such combination therapies will be the tolerability of the treatment regimen. Here, JAK2 is linked to anemia.